Friday bloom on Neuralstem, Inc. (NASDAQ:CUR) [Trend Analysis], stock moved down around -7.43% in early session as its gaining volume of 121315. Neuralstem, Inc. (CUR) reported that completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189 is a new chemical entity and the lead compound in Neuralstem’s neurogenic small molecule program. Enrollment was completed ahead of schedule and data are expected in 3Q 2017.
“Completing the last subject enrolled in the Phase 2 study with NSI-189 for the treatment of MDD earlier than expected is a important clinical development milestone for Neuralstem,” said Rich Daly, Chairman and CEO, Neuralstem. “We now expect results from the Phase 2 study in the 3Q of 2017, and results from the subsequent, 6-month observational study to assess NSI-189’s durability effect will be accessible in the first half of 2018. We are thankful to the individuals and physicians who are participating in these studies and helping us to move closer to potentially bringing this new category of treatment forward.”
The stock showed weekly upbeat performance of 20.83%, which maintained for the month at -6.22%. Similarly, the positive performance for the quarter recorded as 0.00% and for the year was -65.88%, while the YTD performance remained at 7.41%. CUR has Average True Range for 14 days of 0.42.
Benitec Biopharma Limited (NASDAQ:BNTC) [Trend Analysis] pretends to be active mover, stock crashed down around -6.55% to traded at $2.96. BenitecBiopharma Limited (NASDAQ:BNTC) reported that it will present pivotal data from the Company’s hepatitis B virus (HBV) in vivo model at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) meeting, in Shanghai China. Dr David Suhy, Benitec’s Chief Scientific Officer will detail the expanded data set during an oral presentation entitled, ‘Combinations of a DNA-directed RNA interference Agent with Standard of Care Drugs Results in Superior Suppression of Hepatitis B Virus (HBV) in a Chimeric Mouse Model.’
This is the first public forum where Benitec will present the expanded data set from the chimeric mouse study results that were initially declared in December 2016. The data demonstrate that a single administration of one of three DNA-directed RNA interference (ddRNAi) agents, BB-101, BB-102 or BB-103, used in combination with current standard of care agents used to treat HBV, demonstrates importantly robust and sustained suppression of the disease in an in vivo model. (Read Latest [Free Analytic] Facts on NASDAQ:BNTC and Be Updated)
For latest Market Updates Subscribes Here